SCHEMBL806073

SCHEMBL806073

Cc1c(S(=O)(=O)O)sc2c(Cl)cccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PFKFB4 Q16877 6/20 0.56
PFKFB3 Q16875 4/20 0.54
MCL1 Q07820 2/20 0.38
SLC9A1 P19634 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.32
SLC22A12 Q96S37 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL788454 0.98 PFKFB4 (0.55) PFKFB4PFKFB3MCL1SLC9A1CYP1A2
SCHEMBL788498 0.85 PFKFB4 (0.54) PFKFB4PFKFB3MCL1CYP1A2CYP2A6
Potassium Ion SCHEMBL788453 0.83 PFKFB4 (0.55) PFKFB4PFKFB3MCL1CYP1A2CYP2A6
SCHEMBL806216 0.78 PFKFB4 (0.58) PFKFB4PFKFB3MCL1SLC9A1CYP1A2
SCHEMBL3949804 0.77 HTR6 (0.40) PFKFB4PFKFB3
SCHEMBL3950150 0.77 PFKFB4 (0.41) PFKFB4PFKFB3MCL1SLC9A1CYP1A2
SCHEMBL788735 0.77 PFKFB4 (0.57) PFKFB4PFKFB3MCL1SLC9A1CYP1A2
SCHEMBL13032484 0.73 CYP1A2 (0.42) PFKFB4PFKFB3MCL1CYP1A2CYP2A6
SCHEMBL787993 0.73 PFKFB4 (1.00) PFKFB4PFKFB3
SCHEMBL788508 0.73 HSD11B1 (0.47) PFKFB3MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616450-B1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2018-05-02 EP disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA PFKFB4 889/4885PFKFB3 952/4885MCL1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.